Catherine Soller, NP
Nurse Practitioner · Albuquerque, NMNPI 1528290558
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,904 of the $33,147 with a category attached, or 66.1%. 26 manufacturers reported payments, led by Novo Nordisk at 53.4% of the total. Reporting peaked in 2022 at $15,708 and has fallen 86.6% since, to $2,111 in 2025. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $61.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$18K
- Tandem Diabetes Care, Inc.$8K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- Amgen$738
- Dexcom, Inc.$709
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$21,90466%
- Travel & lodging$1,4304%
- Food & beverage$9,78130%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 128 | $17,696 |
| Tandem Diabetes Care, Inc. | 23 | $8,232 |
| Boehringer Ingelheim | 61 | $1,352 |
| Lilly USA, LLC | 60 | $1,137 |
| Amgen(2 entities) | 32 | $738 |
| Dexcom, Inc. | 39 | $709 |
| Bayer | 31 | $700 |
| AstraZeneca(2 entities) | 24 | $431 |
| Sanofi-aventis U.S. LLC | 23 | $319 |
| Insulet Corporation | 26 | $316 |
| Abbott | 15 | $292 |
| Merck | 18 | $254 |
| Xeris Pharmaceuticals, Inc. | 10 | $182 |
| Recordati_rare_diseases_inc. | 7 | $160 |
| Acella Pharmaceuticals, LLC | 8 | $140 |
| Corcept Therapeutics | 4 | $94 |
| Amarin Pharma, Inc. | 6 | $77 |
| Medtronic | 3 | $49 |
| Radius Health, Inc. | 3 | $45 |
| Avion Pharmaceuticals | 3 | $44 |
| AbbVie | 2 | $43 |
| IBSA Pharma Inc. | 3 | $38 |
| Ascendis Pharma Endocrinology Inc | 2 | $37 |
| Johnson & Johnson | 2 | $31 |
| Averitas Pharma Inc. | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$13,967
- t:slim X2 Insulin Pump with Control-IQ$8,200
- Ozempic$2,029
- Wegovy$111
How this compares
$33,147 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 355 | $455,270 |
| JardianceEmpagliflozin | 149 | $159,518 |
| FarxigaDapagliflozin Propanediol | 131 | $100,101 |
| MounjaroTirzepatide | 53 | $80,030 |
| RybelsusSemaglutide | 52 | $78,826 |
| JanuviaSitagliptin Phosphate | 68 | $70,148 |
| InvokanaCanagliflozin | 62 | $70,078 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $45,391 |
| Victoza 3-PakLiraglutide | 45 | $41,513 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $37,075 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $32,723 |
| GlyxambiEmpagliflozin/Linagliptin | 34 | $30,378 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $25,773 |
| KerendiaFinerenone | 35 | $24,678 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $24,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $17,696 | $546,593420 claims |
| Boehringer IngelheimJardiance, Glyxambi | $1,352 | $189,896183 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin N, Humalog Mix 75-25 | $1,137 | $119,570124 claims |
| AstraZenecaFarxiga | $431 | $100,101131 claims |
| MerckJanuvia | $254 | $70,14868 claims |
| Johnson & JohnsonInvokana | $31 | $70,07862 claims |
| BayerKerendia | $700 | $24,67835 claims |
| AmgenProlia | $738 | $22,32813 claims |
| AbbVieArmour Thyroid, Synthroid | $43 | $7,34580 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $140 | $4,29895 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Other nurse practitioner in Albuquerque
- Marisa EscobarAlbuquerque$36K
- Christina ParksAlbuquerque$7K
- Paula JohnsonAlbuquerque$6K
- Nadia Cano VazquezAlbuquerque$6K
- Laura LeblancAlbuquerque$6K
- Dina KotovaAlbuquerque$6K
- Alisha LowdenAlbuquerque$5K
- Lizette Sidransky-UlloaAlbuquerque$5K
- Mary TrujilloAlbuquerque$5K
- Natasha AbruzzoAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.